Purdue Pharma Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Purdue Pharma

Access the complete profile.

Purdue Pharma Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	100 - 500Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing
Address	One Stamford Forum Stamford, CT 06901

Note: Revenues for privately held companies are statistical evaluations.


Purdue Pharma's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Purdue Pharma's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Purdue Pharma is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Purdue Pharma Annual Revenue and Growth Rate

Purdue Pharma	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$100 - $500 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Purdue Pharma's revenues are gauged from an analysis of company filings.

Purdue Pharma's Income Statement (based on Industry Averages)

Purdue Pharma P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Purdue Pharma is developing and marketing. Purdue Pharma doesn't have any recent trademark applications, indicating Purdue Pharma is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
K KNOA PHARMA A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associated with Alcohol Cessation (IAAC), anaphylaxis; pharmaceuticals for use in the treatment of oncology conditions, specifically glioblastoma multiforme (GBM), non Hodgkin lymphoma, solid tumors, melanoma, chronic myelogenous leukemia, hemato-oncology, refractory/relapsed malignancies, alone or in combination with other agents; analgesics; pharmaceuticals, namely, opioid antagonists; syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; syringes filled with opioid antagonists; injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectors filled with opioid antagonists; injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectable pharmaceuticals, namely, opioid antagonists	11/18/2021
K A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associated with Alcohol Cessation (IAAC), anaphylaxis; pharmaceuticals for use in the treatment of oncology conditions, specifically glioblastoma multiforme (GBM), non Hodgkin lymphoma, solid tumors, melanoma, chronic myelogenous leukemia, hemato-oncology, refractory/relapsed malignancies, alone or in combination with other agents; analgesics; pharmaceuticals, namely, opioid antagonists; syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; syringes filled with opioid antagonists; injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectors filled with opioid antagonists; injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectable pharmaceuticals, namely, opioid antagonists	11/18/2021
KNOA PHARMA A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associated with Alcohol Cessation (IAAC), anaphylaxis; pharmaceuticals for use in the treatment of oncology conditions, specifically glioblastoma multiforme (GBM), non Hodgkin lymphoma, solid tumors, melanoma, chronic myelogenous leukemia, hemato-oncology, refractory/relapsed malignancies, alone or in combination with other agents; analgesics; pharmaceuticals, namely, opioid antagonists; syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; syringes filled with opioid antagonists; injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectors filled with opioid antagonists; injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectable pharmaceuticals, namely, opioid antagonists	09/02/2021

See all trademarks and details in the Full Report.

Market Share of Purdue Pharma's Largest Competitors

A competitive analysis shows these companies are in the same general field as Purdue Pharma, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Purdue Pharma. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
HENKEL OF AMERICA	Stamford, CT	100
TRONOX LIMITED	Stamford, CT	7
PURDUE PHARMA	Stamford, CT	5
NCL ACQUISITION	Stamford, CT	5
HENKEL	Stamford, CT	3
PARFUMS DE COEUR	Stamford, CT	2
HIGH RIDGE BRANDS	Stamford, CT	1

Future Competition: Purdue Pharma's Fastest Growing Competitors

These companies are in the same general field as Purdue Pharma and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)